EATG » Pharma industry

Pharma industry

UK court dismisses AbbVie’s legal challenge against the NHS

AbbVie challenged the mechanism used by the NHS to procure hepatitis C treatment in the biggest procurement deal in NHS history. Talha Burki reports. Download the full report published in…

Merck loses bid to revive $200 million Gilead verdict at U.S. high court

The U.S. Supreme Court on Monday handed a defeat to Merck & Co by refusing to hear its appeal of a ruling that it had dishonestly obtained patent rights and…

The patient advocates will see you now: Cancer groups trial the AIDS model for interacting with industry

It’s easy to say you are patient centred – until you are asked to spell out what that means in terms of your processes and practice. Last summer 11 patient…

Pharmaceutical corporations failing children with HIV

MSF criticises pharma for dragging feet on developing HIV drugs for children Geneva, 29 November 2018—Ahead of a Vatican City meeting on scaling up HIV diagnosis and treatment for children,…

2018 Access to Medicine Index

The 2018 Access to Medicine Index finds that a handful of pharmaceutical companies are developing the bulk of urgently needed new medicines for the poor. Amsterdam, the Netherlands, 20 November…

AELIX Therapeutics and Gilead Sciences enter into a clinical research collaboration agreement to evaluate a therapeutic vaccine and TLR7 agonist regimen for HIV cure

AELIX Therapeutics will investigate the safety, immunogenicity, and efficacy of AELIX Therapeutics’ HTI vaccine and Gilead´s Toll-Like Receptor 7 agonist vesatolimod (GS-9620) in HIV-infected individuals BARCELONA, Spain, October 18, 2018:…

Gilead subsidiary to launch authorized generics of Epclusa® and Harvoni® in the US

Gilead subsidiary to launch authorized generics of Epclusa® (sofosbuvir/velpatasvir) and Harvoni® (ledipasvir/sofosbuvir) for the treatment of chronic hepatitis C FOSTER CITY, Calif., Sep. 24, 2018-- Gilead Sciences, Inc.(NASDAQ: GILD) announced today…

Gilead Sciences and Precision BioSciences announce collaboration to develop therapies against hepatitis B virus using ARCUS genome editing

FOSTER CITY, Calif. & DURHAM, N.C., Sep. 12, 2018-- Gilead Sciences (Nasdaq: GILD) and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies…

Merck reinforces commitment to responsible pricing

KENILWORTH, N.J., July 19, 2018 -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, has a long history of responsible pricing. In 2017, Merck issued its second…

Novartis drops antibiotics research program

Ceasing work on several experimental antimicrobial projects   CIDRAP News: Novartis drops antibiotic development program “Antibiotic development efforts were dealt a blow when drug maker Novartis AG announced its…

1 2 3 7